AtaiBeckley Inc. (ATAI)
ATAI · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2025
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 |
| Report filed | Mar 6, 2026 | · |
| Revenue | 4,089 | 308 |
| Research and development | 53,062 | 55,455 |
| General and administrative | 65,088 | 47,544 |
| Total operating expenses | 648,150 | 102,999 |
| Operating income | -644,061 | -102,691 |
| Interest expense | 1,162 | 3,124 |
| Interest and investment income | 1,478 | 778 |
| Share of profit of equity-method investments | 0 | -2,000 |
| Other income (expense), net | -3,059 | 5,514 |
| Total non-operating income (expense) | -15,788 | -45,714 |
| Income before income taxes | -659,849 | -148,405 |
| Income tax expense | 298 | -356 |
| Net income including non-controlling interests | -660,147 | -150,049 |
| Net income to non-controlling interests | -100 | -780 |
| Net income | -660,047 | -149,269 |
| Net income to common shareholders | -660,047 | -149,269 |
| Earnings per share, basic | -2.91 | -0.93 |
| Earnings per share, diluted | -2.91 | -0.93 |
| Weighted average shares, basic | 226,532,786 | 160,159,983 |
| Weighted average shares, diluted | 226,532,786 | 160,159,983 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestShare of profit of equity-method investments its share of companies it partly owns
us-gaap:IncomeLossFromEquityMethodInvestmentsOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
us-gaap:NetIncomeLossAttributableToNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding